1. Background {#sec1}
=============

Alzheimer disease (AD) is a chronic neurodegenerative disease characterized by short-term memory loss in the early disease stages and progressive cognitive and functional deficits as the disease advances. The clinical symptoms result from the deposition of two toxic proteins, β-amyloid (Aβ) and tau, which give rise to neuritic plaques and neurofibrillary tangles, respectively [@bib1]. The clinical appearance of AD is the direct result of neuronal dysfunction and death, which is manifested by brain atrophy and hypometabolism.

Brain imaging is increasingly used to measure AD-associated changes in vivo. Amyloid positron emission tomography (PET), a novel Food and Drug Administration--approved imaging technology, uses selective Aβ tracers to visualize brain amyloidosis and can reliably detect the presence of neuritic plaques in the symptomatic and presymptomatic stages. Brain atrophy is best evaluated with longitudinal studies of magnetic resonance imaging (MRI). The atrophic changes are first noticeable in the medial temporal lobe, eventually spreading through the remainder of the brain as the disease progresses [@bib2]. Contributing to the neuronal death, brain hypometabolism, a decrease in the brain metabolic activity, can be visualized using F^18^-fluorodeoxyglucose (FDG) PET or single photon emission tomography. The hallmark pattern in AD is early hypometabolism of the posterior cingulate, lateral temporal, and parietal lobes with spread to the frontal lobes as the disease progresses [@bib3].

Seventy to eighty percent of sporadic AD can be attributed to genetic risk [@bib4], [@bib5]. Recent large-scale genome-wide association studies (GWASs) have discovered more than 20 AD gene variants that confer genetic risk [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]. Among these variants is the apolipoprotein E (*APOE*) gene, which is the most established genetic risk factor for AD. Individuals with a single *APOE* ε4 allele have a three-fold increase in AD risk, whereas homozygotes have a 12-fold increase [@bib12]. apoE is a major protein component of chylomicrons and is highly expressed in both liver and brain, where it plays a role in lipid metabolism and is thought to be involved in the breakdown of Aβ, both inside and outside of cells. The apoE4 protein is less effective in clearing Aβ, providing a possible explanation for the increased risk of amyloid buildup [@bib13]. With the help of imaging studies, *APOE* ε4 allele was found to be strongly associated with brain amyloidosis [@bib14], [@bib15], atrophy [@bib16], and hypometabolism [@bib17], [@bib18]. These data indicate that valuable observations related to gene function can be gathered with imaging phenotypes.

Many of the remaining top 20 AD variants have also been implicated in brain metabolism and neurodegeneration. Several *SORL1* variants, *EPHA1* rs11771145, and *CR1* rs6656401 were found to be associated with hippocampal atrophy and cerebrovascular or cardiovascular disease [@bib19], [@bib20]. Additionally, various research groups have shown that *ABCA7* rs3764650, *MS4A6A* rs983392, *MS4A6A* rs610932 and rs11230161, *BIN1* rs6733839 and rs744373, *CR1* rs1408077, *CR1* rs6656401, *CR1* rs3818361, *PICALM* rs3851179, *CLU* rs11136000 and rs2279590, *CD2AP* rs10948363, and *CD33* rs3865444 are all associated with MRI-measured brain atrophy on MRI [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27]. *BIN1* rs7561528 was found to be significantly associated with both hippocampal volume and FDG PET brain metabolism [@bib28]. The studies mentioned have unquestionably contributed to the field of imaging genetics and AD research as a whole, but many of these studies have either analyzed the effect of a single gene variant at a time [@bib19], [@bib20], [@bib21], [@bib22], [@bib24], [@bib26], [@bib27] or investigated the association between a polygenic risk score with the imaging trait, which does not allow us to interpret the individual contribution of genetic variants [@bib23]. The commonly used univariate imaging genetics approach ignores the fact that in any given human subject, many of these risk variants are simultaneously present, and the genetic contribution of each variant should be investigated in the presence of the rest and not in isolation. In addition, these studies have investigated the effects in the pooled samples consisting of asymptomatic individuals, of whom only a portion harbor AD pathology, as well as symptomatic individuals who are in different stages of the disease. Such an approach would miss any stage-specific associations that might occur for genes that influence the timing and course of development of disease traits (e.g., early vs. late neurodegeneration or amyloidosis, early vs. late impairment in a specific cognitive domain) and explain, at least in part, AD heterogeneity.

Using a multivariable approach across the disease spectrum allows for accurate modeling of this complex polygenic disease that is constantly evolving. Here, we report a comprehensive analysis of the associations of all well-validated AD risk variants from recent large-scale GWAS studies with two markers of neurodegeneration---brain gray matter density (GMD) and brain glucose metabolism. Our goal was to establish the relative contribution of the top 20 AD risk genes to changes in GMD and metabolic dysfunction. We hypothesized that we would find gene variants that show a profound effect on these two neurodegenerative phenotypes and that some variants will show associations in a stage-specific manner.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

We sourced our study data from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). ADNI is an international longitudinal study with approximately 50 sites across the United States and Canada that was launched in 2003. ADNI\'s goal is to track the progression of AD using clinical and cognitive tests, MRI, FDG PET, amyloid PET, cerebrospinal fluid, and blood biomarkers (<http://adni.loni.usc.edu/study-design>).

ADNI has undergone three study cycles: ADNI1, ADNI GO, and ADNI2. Our study population was composed of participants from all three stages [@bib29]. The MRI and FDG PET analyses included all subjects with GWAS and baseline MRI or FDG PET data that were successfully preprocessed. A total of 1564 ADNI subject had baseline MRI and GWAS data. Of those, 65 failed in the MRI preprocessing steps and were excluded from our structural analyses. Our final MRI cohort consisted of 441 cognitively normal (NC) subjects, 764 mild cognitive impairment (MCI) subjects, and 294 dementia subjects (total *N* = 1499). As not all ADNI1 subjects received FDG PET, our FDG PET cohort was smaller and consisted of 381 NC, 634 MCI, and 243 dementia subjects (total *N* = 1258). There were 59 subjects with available FDG PET data whose MRI scans failed in the preprocessing steps as described previously. These subjects were included in our FDG PET analyses.

The clinical characteristics of the ADNI cohort were described previously [@bib30]. Diagnosis of AD was based on the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association criteria [@bib31]. AD subjects were required to have Mini--Mental State Examination (MMSE) [@bib32] scores between 20 and 26 and a Clinical Dementia Rating (CDR) scale score of 0.5--1 at baseline [@bib33]. Qualifying MCI subjects had memory complaints but no significant functional impairment, scored between 24 and 30 on the MMSE, had a global CDR score of 0.5, a CDR memory score of 0.5 or greater, and objective memory impairment on Wechsler Memory Scale--Logical Memory II test [@bib34]. NC subjects had MMSE scores between 24 and 30, a global CDR of 0, and did not meet criteria for MCI and AD. Subjects were excluded if they refused or were unable to undergo MRI; had other neurological disorders, active depression, or history of psychiatric diagnosis, alcohol, or substance dependence within the past 2 years; less than 6 years of education; or were not fluent in English or Spanish. The full list of inclusion/exclusion criteria may be accessed on pages 23--29 of the online ADNI protocol (<http://www.adni-info.org/Scientists/ADNIStudyProcedures.html>). Written informed consent was obtained from all participants.

2.2. Gene variant selection and imputation {#sec2.2}
------------------------------------------

ADNI-1 participants were genotyped using the Illumina Human610-Quad BeadChip array, whereas ADNI-2/GO participants were genotyped using the Illumina HumanOmniExpress BeadChip (Illumina, Inc., San Diego, CA). Our decision to include gene variants was based on the AD GWAS studies that discovered these variants to date [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]. Genes previously associated with the defining AD pathologic hallmark--amyloid pathology were also included in our study [@bib35], [@bib36], [@bib37] ([Supplementary Table 1](#appsec1){ref-type="sec"}). The total number of variants selected was 36.

*ABCA7* rs3752246, *BIN1* rs6733839, *CASS4* rs7274581, *CD2AP* rs9349407, *CELF1* rs10838725, *INPP5D* rs35349669, *PTK2B* rs2883497, *SORL1* rs11218343, and *SORL1* rs1131497 were not genotyped on either ADNI GWAS array and needed full imputation. The following variants were only genotyped on one of the platforms and needed partial imputation: *NME8* rs2718058 in ADNI1 and *CLU* rs933194, *DSG2* rs8093731, *MEF2C* rs190982, and *ZCWPW1* rs1476679 in ADNI-GO/2 ([Supplementary Table 2](#appsec1){ref-type="sec"}). The imputation procedures have been previously described [@bib38]. Imputation was performed using MACH and minimac methodology and the 1000 Genomes project ([www.1000genomes.org](http://www.1000genomes.org){#intref0035}) as the reference panel. The accuracy threshold was set at r^2^ = 0.30.

We assessed Hardy-Weinberg equilibrium (HWE) using the \--hardy option in PLINK. In the test, we used a quantitative phenotype (global cortical metabolism) and a case-control phenotype. Our results indicate that all 27 single nucleotide polymorphisms (SNPs) do not show any evidence of deviation from HWE (*P*-value \> .01). The accepted significance threshold for declaring SNPs thought to be in HWE is *P*-value \< .001.

Nine of our 20 genes were represented by more than one SNP. Given that such variants could be in linkage disequilibrium (LD) and introduce colinearity bias, we performed LD analyses followed by Cohen kappa (κ) statistics ([Supplementary Table 3 and Supplementary Figure 1](#appsec1){ref-type="sec"}). When variants providing identical information (those with high LD and high κ) were detected, we chose the SNP with the smallest amount of missing data. This reduced our variants from 36 to 27.

We assessed the allele frequencies for each gene variant. SNPs were coded by minor allele dosage except for the following: *ABCA7* rs3764650 GG/GT versus TT, *CASS4* rs7274581 CC/TC versus TT, *CLU* rs9331949 AG/GG versus AA, *DSG2* rs8093731 TT/TC versus CC, *FERMT2* rs17125944 CC/TC versus TT, and *SORL1* rs112183431 CC/TC versus TT where the minor allele homozygote frequency was less than 2%.

2.3. MRI and FDG PET data acquisition and analyses {#sec2.3}
--------------------------------------------------

The MRI acquisition and preprocessing protocols can be found on [www.adni-info.org](http://www.adni-info.org){#intref0040}. ADNI MRI data acquisition and preprocessing have been previously described elsewhere [@bib39], [@bib40], [@bib41]. Briefly, we downloaded preprocessed MRI data from LONI IDA (<https://ida.loni.usc.edu>[)]{.ul} [@bib42]. Seven hundred eighty-five subjects had 3T scans available, and for the remaining 715 subjects, we used 1.5T data. MRI field strength was included as a covariate in all MRI analyses. We analyzed all scans using voxel-based morphometry in Statistical Parametric Mapping (SPM8), as described previously [@bib43], [@bib44]. Scans were downloaded from the ADNI site in NifTI format, coregistered to MNI space, bias corrected, and segmented into gray matter (GM), white matter, and cerebrospinal fluid compartments using SPM templates. GM maps were converted to 1 × 1 × 1 mm voxel resolution and smoothed using 10-mm full-width half maximum Gaussian kernel yielding GM density data. Total intracranial volume (ICV) and baseline mean medial temporal lobe thickness measures were extracted for each subject using FreeSurfer version 5.1, as described previously [@bib45], [@bib46]. The medial temporal region of interest included the entorhinal, fusiform, parahippocampal, and temporopolar cortical areas.

The FDG PET acquisition and preprocessing protocols can be found on [www.adni-info.org](http://www.adni-info.org){#intref0050}. PET scanners and related equipment across sites were held to the same qualifications, calibration, and normalization standards, as described in detail [@bib47]. We downloaded preprocessed FDG PET data from LONI IDA (<https://ida.loni.usc.edu>). These scans were already averaged, aligned to a standard space, resampled to a standard image and voxel size (2 × 2 × 2 mm), smoothed to a uniform resolution as previously described [@bib47]. The downloaded images were aligned to each corresponding MRI image on a subject-by-subject basis in MNI space using SPM8, as previously described [@bib46]. Each scan\'s intensity was scaled to the pons to create standard uptake value ratio (SUVR) images. Finally, baseline mean FDG SUVR in bilateral posterior cingulate was extracted for each subject [@bib48], [@bib49].

2.4. Statistical analyses {#sec2.4}
-------------------------

### 2.4.1. R statistical analyses {#sec2.4.1}

The distributions of clinical and demographic characteristics (age, sex, education, MMSE, *APOE* ε4 allele dosage, diagnosis) for each variant were analyzed using *t* tests or chi-square tests with two-sided *P*-values as appropriate.

Our main analyses were done in R. First, we performed stepwise linear regression with all 27 AD risk variants as predictors and age, gender, education, and *APOE* ε4 allele dosage as covariates in the pooled sample and then in each diagnostic group. We used medial temporal GMD or posterior cingulate SUVR, respectively, as outcome measures. Additional covariates were the diagnosis in the pooled analyses and magnetic field strength and ICV in all MRI analyses. The decision to exclude variables in the stepwise regression models was based on the Akaike information criterion using the critical *P*-value of .157 [@bib50]. Given that all the risk genes were previously validated (i.e., all were candidate genes) and we used a multivariable model, we set our significance threshold at *P* \< .05. After discovering stage-specific genetic influences, we repeated the pooled sample analyses introducing interaction terms between the genetic variants retained in our models and diagnosis.

### 2.4.2. Analyses in imaging space {#sec2.4.2}

All imaging analyses were done in exploratory fashion. We reproduced the final stepwise regression models using voxelwise regression in SPM8 for visualization purposes to explore, on a whole-brain level, the extent and spatial pattern of these imaging genetic associations established using a region of interest approach. These models included all variants retained in the R stepwise linear regression models and were covaried for age, gender, education, and *APOE* ε4 allele dosage. Consistent with our original regression model, the pooled analyses also included diagnosis as a covariate, and the MRI analyses were additionally controlled for MRI field strength and ICV. Due to the exploratory nature of our secondary results, we used a less-stringent visualization voxelwise threshold, which was uncorrected *P* \< .01 with a minimum cluster size (k) of 50 voxels. Next, we applied cluster-level family-wise error (FWE) and false discovery rate (FDR) correction and sought out the within-cluster peak effects for all genetic variants identified in our models.

3. Results {#sec3}
==========

Group comparisons of demographic characteristics and distributions of the genotypes that were retained in the regression models are shown in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} for the MRI and PET samples, respectively. As expected, AD subjects were the oldest, least educated, had the greatest frequency of *APOE* ε4 homo- and heterozygotes, and performed the worst on MMSE ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). There were no significant differences in age, gender, education, MMSE, and *APOE* ε4 allele dosage distribution between carriers and noncarriers or by allele dosage for any of the genotypes except the following: *DSG2* minor allele carriers were more likely to be male (*P* = .028 in the FDG sample) and less likely to be *APOE* ε4 carriers (*P* = .04 in the MRI sample); *EPHA1* rs11767557 minor allele carriers were less likely to be *APOE* ε4 carriers and had significantly higher MMSE scores in the FDG sample (*P* = .037 and *P* = .047, respectively); *SORL1* rs11218343 minor allele carriers were less educated and more likely to be male in both samples (MRI: *P* = .01 and *P* = .008, and FDG *P* = .008 and *P* = .026, respectively), and *ZCWPW1* risk allele carriers were significantly less educated and had higher MMSE scores in both samples (MRI *P* = .0012 and *P* = .034, and FDG *P* = .025 and *P* = .034, respectively). For completeness, the allele dosage for all 27 variants including the ones not retained in our models can be seen in [Supplementary Tables 4 and 5](#appsec1){ref-type="sec"}.

*APOE* ε4 showed the expected positive association with GMD in the NC and MCI group ([Fig. 1](#fig1){ref-type="fig"} top). In the symptomatic MCI group, we saw a strong hippocampo-centric pattern, indicating that MCI carriers had greater hippocampal loss of GMD compared to MCI noncarriers. In the dementia group, we found the opposite association. *APOE* ε4-negative dementia subjects had greater cortical loss of GMD than *APOE* ε4-positive subjects, indicative of greater cortical neurodegeneration. *APOE* ε4 was associated with widespread hypometabolism in the MCI group ([Fig. 1](#fig1){ref-type="fig"} bottom). *APOE* ε4 showed a much less pronounced effect in the dementia stage indicating that both carriers and noncarriers experienced significant, widespread hypometabolic changes.

3.1. MRI analyses {#sec3.1}
-----------------

### 3.1.1. Pooled sample {#sec3.1.1}

In the pooled sample, the stepwise linear regression model achieved an R^2^ = 0.4, *P* \< .0001. *SLC24A4*/*RIN3* rs10498633 was the only variant that was significantly associated with mean medial temporal lobe GMD in the pooled sample (χ^2^ = 11.8, *P* = .003). *ABCA7* rs3752246 and *FERMT2* rs17125944 were retained in the regression output based on the selection criteria but were not statistically significant. See [Fig. 2](#fig2){ref-type="fig"} for the exploratory visualization of these associations and [Table 3](#tbl3){ref-type="table"} for FWE- and FDR-corrected cluster-level results and within-cluster peak effects for genetic variants identified in our models.

### 3.1.2. Analyses within diagnostic groups {#sec3.1.2}

We found neither significant nor trend-level associations in the NC group. In the MCI group, the model achieved an R^2^ = 0.26. *SLC24A4*/*RIN3* rs10498633 (χ^2^ = 11.3, *P* = .004) and *ZCWPW1* rs1476679 (χ^2^ = 7.3, *P* = .026) reached significance. *CELF1* rs10838725 (χ^2^ = 5.2, *P* = .073) was trending. In the dementia group, the model achieved an R^2^ = 0.19, *P* \< .0001. *ABCA7* rs3752246 (χ^2^ = 8.5, *P* = .014), *EPHA1* rs11771145 (χ^2^ = 11.6, *P* = .003), and *INPP5D* rs35349669 (χ^2^ = 6.4, *P* = .042) were significantly associated with mean medial temporal lobe GMD. *SLC24A4*/*RIN3* rs10498633 (χ^2^ = 5.4, *P* = .068) was trending. See [Fig. 2](#fig2){ref-type="fig"} for the exploratory pattern of these associations.

Next, we repeated the pooled sample analyses introducing interaction terms between the genetic variants retained in our models and diagnosis. The following variants showed significant interaction effect with diagnosis---*EPHA1* rs11771145 (F = 3.2, *P* = .01) and *SLC24A4*/*RIN3* (F = 2.7, *P* = .03). Please note that the R statistical analyses and the analyses in imaging space might differ. This is because in our R statistics model, we use a circumscribed ROI, in the case of MRI, the medial temporal region, while the whole-brain exploratory results show the effect of the variant across the brain.

3.2. FDG PET analyses {#sec3.2}
---------------------

### 3.2.1. Pooled sample {#sec3.2.1}

In the pooled sample, the stepwise linear regression model achieved an R^2^ = 0.13, *P* \< .0001. *EPHA1* rs11767557 showed significant associations with brain metabolism (χ^2^ = 6.3, *P* = .042). *PTK2B* rs28834970 (χ^2^ = 5.6, *P* = .059), *MS4A6A* rs610932 (χ^2^ = 5.5, *P* = .065) and *SLC24A4*/*RIN3* rs10498533 (χ^2^ = 4.6, *P* = .098) showed trend-level associations. *CLU* rs11136000 and *EPHA1* rs11771145 were included in the model based on the selection criteria but were not statistically significant.

See [Fig. 3](#fig3){ref-type="fig"} for the exploratory visualization of these associations and [Table 4](#tbl4){ref-type="table"} for FWE- and FDR-corrected cluster-level results and within-cluster peak effects for genetic variants identified in our models.

### 3.2.2. Analyses within diagnostic groups {#sec3.2.2}

In the NC group, the stepwise linear regression model achieved an R^2^ = 0.14, *P* \< .0001. *SLC24A4*/*RIN3* rs10498533 (χ^2^ = 6.3, *P* = .043), *NME8* rs2718058 (χ^2^ = 6.0, *P* = .049), and *CD2AP* rs9349407 (χ^2^ = 6.1, *P* = .048) showed significant associations, whereas *DSG2* rs8093731 (χ^2^ = 3.4, *P* = .064), *CR1* rs12034383 (χ^2^ = 4.9, *P* = .087), and *CELF1* rs10838725 (χ^2^ = 5.386, *P* = .068) were trending. *CLU* rs9331949 and *PTK2B* rs28834970 were included in the model based on the selection criteria but were not statistically significant. In the MCI group, the stepwise linear regression model achieved an R^2^ = 0.09, *P* \< .0001. *CLU* rs9331949 was trending (χ^2^ = 3.4, *P* = .065), whereas *MS4A6A* rs610932 was included based on the selection criteria but was not statistically significant. In the dementia stage, the model achieved an R^2^ = 0.07, *P* = .034. *SORL1* rs11218343 showed trend-level significance (χ^2^ = 3.5, *P* = .063), whereas *NME8* rs2718058 and *CD2AP* rs9349407 were included based on the selection criteria but were not statistically significant. See [Fig. 3](#fig3){ref-type="fig"} for the exploratory visualization of these associations.

Next, we repeated the pooled sample analyses introducing interaction terms between the genetic variants retained in our models and diagnosis. The following variants showed significant interaction effect with diagnosis---*CD2AP* rs9349407 (F = 2.4, *P* = .04), *CLU* rs9331949 (F = 3.5, *P* = .03), and *NME8* rs2718058 (F = 3.1, *P* = .01), *CR1* rs12034383 (F = 2.3, *P* = .06) and *SORL1* rs11218343 (F = 2.9, *P* = .06) showed trend-level interactions. Please note that the R statistical analyses and the analyses in imaging space might differ. This is because in our R statistics model, we use a circumscribed ROI, in the case of FDG PET the posterior cingulate region, while the whole-brain exploratory results show the effect of the variant across the brain.

4. Discussion {#sec4}
=============

To our knowledge, this is the first comprehensive analysis of the effect of the top 20 AD risk variants on GMD and brain metabolism. In our MRI analyses, we found no genetic influences on GMD in NC. In the MCI stage, *SLC24A4*/*RIN3* rs10498633 and *ZCWPW1* rs1476679 showed significant effects, whereas in the dementia stage, *ABCA7* rs3752246, *EPHA1* rs11771145, and *INPP5D* rs35349669 were significantly associated with GMD. In our FDG PET analyses, the only significant associations were seen in the NC control group for *SLC24A4*/*RIN3* rs10498533, *NME8* rs2718058, and *CD2AP* rs9349407. The reported associations of *ABCA7*, *ZCWPW1*, and *INPP5D* with GMD, and *CD2AP* with brain metabolism, are novel.

Many of our variants displayed stage-specific associations, which is likely due to the nature of AD pathological biomarker changes from the presymptomatic stage to dementia. These stage-specific associations are in agreement with the biomarker progression as proposed by Jack et al. [@bib51]. Jack\'s biomarker progression model postulates that neurodegenerative changes begin in the late asymptomatic stages as NC individuals start to transition to MCI and that FDG PET abnormalities precede brain atrophy [@bib51]. Both neurodegenerative biomarkers become progressively more abnormal over the course of the disease. Our findings agree with this model. Our results indicate neither significant nor trend-level associations with GMD in the NC group, but significant associations were detected in the MCI and dementia stages. We also see a modality effect progression that fits with the Jack model. *SLC24A4/RIN3* shows significant association with brain metabolism in the presymptomatic stages and associations with GMD in the MCI group.

Recent analyses from our group on the top 20 AD genes and brain amyloidosis revealed that, after *APOE* ε4, ABCA7 had the strongest effect on brain amyloidosis, with the effect being most pronounced in the MCI stage [@bib52]. In the present study, we observe a strong association of *ABCA7* with GMD in the dementia group. These associations also seem to follow the biomarker progression, as Aβ deposition begins in the presymptomatic to early MCI phase and global decreases in GMD begin in late MCI to dementia phase. Associations of *ABCA7* with both brain atrophy [@bib21] and amyloidosis [@bib35], [@bib36], [@bib37] have been previously reported.

In a similar manner, our previous work showed that *EPHA1*\'s strongest effect on brain amyloidosis is in the prodromal phase [@bib52]. In the present study, our MRI results show a significant association with GMD in the dementia stages only. To date, two additional studies have described *EPHA1* associations with brain atrophy [@bib53], [@bib54] and one also detected an association with brain metabolism as we did here [@bib53].

Next, we found it pertinent to briefly review the literature on the function and central nervous system associations for each of the genes in our models.

ATP-binding cassette subfamily A member 7 (*ABCA7*) encodes a 2146--amino acid member of the ABC transporter family comprised of proteins involved in lipid transport [@bib55]. *ABCA7* is highly expressed in the central nervous system and in microglia [@bib56]. Loss of function of endogenous *ABCA7* increases β-secretase cleavage of APP to Aβ in brain lysates and in murine models [@bib57]. Fifteen *ABCA7* loci were recently evaluated for associations with cerebrospinal fluid Aβ and tau levels, brain atrophy, and brain hypometabolism. Several *ABCA7* variants had significant associations with amyloid deposition, although an association with brain atrophy was not reported there [@bib58]. However, another group has previously found such an association in a different independent imaging genetic cohort [@bib21]. Additionally, one rare missense mutation variant of *ABCA7* (rs7297358) was found to be protective for AD [@bib59].

The CD2-associated protein gene (*CD2AP*) encodes a 639--amino acid scaffolding protein that is named by its association with the T-cell and natural killer cell adhesion molecule cluster of differentiation 2 (CD2). *CD2AP* is a cytokinetic regulator that might be influencing neuronal survival by reducing the potency of glial cell--derived neurotrophic factor [@bib60]. In cell culture, *CD2AP* suppression results in lower levels of APP, less Aβ release, and a lower Aβ~42~/Aβ~40~ ratio while having little to no effect on Aβ deposition [@bib61]. *CD2AP* knockdown significantly increases Aβ protein levels, whereas APP remained at a similar level to the wild type [@bib62]. Recent research in *CD2AP* knockout mice shows that *CD2AP*\'s association with LOAD risk may be at least in part due to an effect on the cerebrovascular unit [@bib63]. To our knowledge, there are no reported imaging associations of *CD2AP* to date.

EPH receptor A1 (*EPHA1*) belongs to the EPH family of receptor tyrosine kinases. *EPHA1* codes for a 976--amino acid protein with a single kinase domain [@bib64]. *EPHA1* is highly expressed in cerebral cortex and hippocampus (<http://www.proteinatlas.org/ENSG00000146904-EPHA1/tissue>) and plays a crucial role in cortical and axonal development [@bib65], [@bib66]. *EPHA1* directs contact-dependent bidirectional signaling by binding the membrane-bound ephrin-A family of ligands [@bib67], [@bib68]. As already discussed, EPHA1 has been previously associated with brain atrophy and brain metabolism [@bib53], [@bib54].

Inositol polyphosphate-5-phosphatase D (*INPP5D*) encodes a 1888--amino acid protein that plays a role in a number of inflammatory pathways and in regulation of cytokine signaling [@bib69], [@bib70]. *INPP5E*, a closely related gene to *INPP5D*, is a crucial regulator of autophagy [@bib71]. Autophagy has been shown in many instances to be dysregulated in AD [@bib72], [@bib73], [@bib74]. *INPP5D* may also play a role in suppression of cytokine release from microglia or astrocytes [@bib75]. *INPP5D* has been significantly associated with several central nervous system pathologies, including macroscopic and microscopic infarcts, Lewy bodies, and hippocampal sclerosis [@bib76].

NME family member 8 (*NME8*) encodes a 588--amino acid protein kinase. Until recently, *NME8* was associated with nonneurologic diseases such as primary ciliary dyskinesia [@bib77] and osteoarthritis [@bib78], [@bib79]. In a recent ADNI study, however, *NME8* rs2718058 was shown to have a neuroprotective effect against hippocampal atrophy and brain hypometabolism [@bib80].

Solute carrier family 24 (sodium/potassium/calcium exchanger) member 4 (*SLC24A4*)/Ras and Rab Interactor 3 (*RIN3*) are indicated in AD together because the candidate polymorphism lies between both genes on chromosome 14q32.12. *SLC24A4* encodes a 622--amino acid potassium-dependent sodium-calcium exchanger [@bib81]. *SLC24A4* appears to take part in lipid metabolism [@bib82]. *SLC24A4* CpG methylation sites were also associated with Aβ burden and tau pathology [@bib83]. In a recent study, *SLC24A4* knockout mice showed brain glucose hypometabolism [@bib84]. Interestingly, we found a similar effect in NC.

*RIN3* encodes a 985--amino acid guanine exchange factor for RAB5B and RAB31 and plays an important role in the transport of early endosomes [@bib85], [@bib86]. In a transgenic model, a mutation in APP was shown to contribute to early endosomal abnormalities and enlargement, which leads to loss of cholinergic neurons [@bib87]. RAB GTPase expression is increased in MCI subjects and in aging brains [@bib88]. *RIN3* also interacts with *BIN1*, which has recently been linked to tau pathology [@bib89]. To our knowledge, there are no reported imaging associations of *RIN3* to date.

Zinc finger CW-type and PWWP domain containing 1 (*ZCWPW1*) codes for a 648--amino acid protein that has recently been identified as a risk variant for late-onset AD [@bib90]. Zinc fingers including *ZCWPW1* are crucial components of epigenetic regulation [@bib91], [@bib92], [@bib93]. To our knowledge, there are no reported imaging associations of *ZCWPW1* to date.

The *APOE* ε4 allele dosage effect on cortical GMD warrants some discussion. Structurally, we found the expected negative association of *APOE* ε4 allele dosage with GMD in NC and MCI with a strong predilection for the medial temporal lobe. In the dementia group, however, *APOE* ε4-negative individuals showed more profound atrophy than *APOE* ε4 carriers with a broad neocortical distribution. Given that a far greater proportion of *APOE* ε4-negative dementia subjects were amyloid negative (94% vs. 28% of the amyloid-positive dementia subjects, *P* \< .0001), one could safely conclude that the profound cognitive decline of many of these subjects is due to other neurodegenerative diseases. Thus, the finding greater atrophy in *APOE* ε4 noncarrier dementia subjects in extra-hippocampal locations is not surprising.

Several strengths and limitations of our work are worth noting. The major strength of our study is our multivariable approach. This allows us to more accurately model the associations with AD biomarkers as they exist in vivo. Using ADNI is another strength as the ADNI protocol includes a rigorous clinical, biomarker, and genetic characterization for all enrolled subjects. By standardizing their data collection and processing strategies, ADNI minimizes between-site variations as much as possible. ADNI is a multisite study modeled by clinical trials. As such, ADNI uses more stringent inclusion and exclusion criteria typical of clinical trial methodology. Hence all observations made here need to be further replicated in the general population. Another limitation is that our study design is a cross-sectional analysis. From our data alone, it is not possible to reliably draw conclusions about changes in metabolism or atrophy over time. We do, however, intend to address this in future studies by taking a longitudinal approach to our work. Despite this limitation, this study has identified several key genes that may exert their effect in specific stages, which need to be examined in future research.

In conclusion, we found several AD risks and protective loci that may play a key role in GMD and brain metabolism. We also noted stage-specific associations for certain variants, which may follow a specific progression of AD biomarkers throughout the disease. Importantly, many of these stage associations take place in the context of the proposed biomarker timeline.Research in Context1.Systematic review: Our goal was to analyze the effects of the top 20 Alzheimer disease (AD) risk genes on brain gray-matter density (GMD) and metabolism. We assessed relevant literature by searching PubMed and Science Direct for studies describing imaging genetics associations in AD.2.Interpretation: *SLC24A4*, *ABCA7*, and *EPHA1* have significant stage-specific associations that followed the predicted biomarker pathway. We discovered novel associations of *ZCWPW1*, *INPP5D*, and *ABCA7* with brain GMD and *CD2AP* with brain metabolism.3.Future directions: Future longitudinal studies of the observed associations will aptly measure defined changes over time. This approach will be critical in accurately modeling the genetic effects on disease progression.
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![*APOE4* effect on brain atrophy (top) and hypometabolism (bottom). Results are displayed using *P* \< .01 (uncorrected) and cluster size (k) of 50 voxels. Abbreviations: FDG PET, F18-fluorodeoxyglucose positron emission tomography; MRI, magnetic resonance imaging.](gr1){#fig1}

![Stepwise linear regression results---MRI analysis. Results are displayed using *P* \< .01 (uncorrected) and cluster size (k) of 50 voxels. Abbreviation: MRI, magnetic resonance imaging.](gr2){#fig2}

![Stepwise linear regression results of FDG PET. Results are displayed using *P* \< .01 (uncorrected) and cluster size (k) of 50 voxels. Abbreviation: FDG PET, F18-fluorodeoxyglucose positron emission tomography.](gr3){#fig3}

###### 

Descriptive characteristics and distribution of the genotypes of the MRI sample

  Variables                            NC (*N* = 441)   MCI (*N* = 764)   DEM (*N* = 294)   *P*
  ------------------------------------ ---------------- ----------------- ----------------- ------------
  Age, mean years (SD)                 74.1 (5.7)       72.6 (7.6)        74.6 (7.9)        **\<.001**
  Sex, *N* male (%)                    222 (50)         453 (59)          165 (56)          **.01**
  Education, mean years (SD)           16.4 (2.6)       16.0 (2.8)        15.2 (3.0)        **\<.001**
  MMSE, mean (SD)                      29.1 (1.1)       27.6 (1.8)        23.3 (2.1)        **\<.001**
  *APOE* ε4, % 0/1/2                   71/27/2          49/40/11          34/47/19          **\<.001**
  *ABCA7* rs3752246, % 0/1/2           69/29/2          68/28/4           67/30/3           .58
  *CELF1* rs10838725, % 0/1/2          46/45/9          44/46/10          45/48/7           .45
  *EPHA1* rs11771145, % 0/1/2          44/44/12         43/45/12          45/42/13          .95
  *FERMT2* rs17125944, % 0/1           85/15            84/16             78/22             **.02**
  *INPP5D* rs35349669, % 0/1/2         30/48/22         30/46/24          26/51/23          .52
  *SLC24A4/RIN3* rs10498633, % 0/1/2   60/35/5          61/34/5           60/35/5           .99
  *ZCWPW1* rs1476679, % 0/1/2          50/41/9          51/41/8           60/33/7           .08

Abbreviations: MRI, magnetic resonance imaging; NC, normal control; MCI, mild cognitive impairment; DEM, dementia; SD, standard deviation.

NOTE. Bold text indicates a significant *P* value (*P* \<0.05).

###### 

Descriptive characteristics and distribution of the genotypes of the FDG PET sample

  Variables                            NC (*N* = 381)   MCI (*N* = 634)   DEM (*N* = 243)   *P*
  ------------------------------------ ---------------- ----------------- ----------------- ------------
  Age, mean years (SD)                 74.3 (6.2)       72.6 (7.6)        75.0 (7.7)        **\<.001**
  Sex, *N* male (%)                    190 (50)         380 (60)          148 (61)          **.003**
  Education, mean years (SD)           16.4 (2.7)       16.1 (2.7)        15.4 (2.9)        **\<.001**
  MMSE, mean (SD)                      29.0 (1.2)       27.8 (1.8)        23.1 (2.8)        **\<.001**
  *APOE* ε4, % 0/1/2                   73/25/2          51/38/11          33/50/17          **\<.001**
  *CD2AP* rs9349407, % 0/1/2           49/44/7          53/40/7           49/40/11          .22
  *CELF1* rs10838725, % 0/1/2          48/42/10         44/46/10          43/50/4           .27
  *CLU* rs11136000, % 0/1/2            36/50/14         37/50/13          43/42/15          .28
  *CLU* rs9331949, % 0/1               95/5             97/3              95/5              .31
  *CR1* rs12034383, % 0/1/2            14/49/37         15/48/37          21/46/33          .19
  *DSG2* rs8093731, % 0/1              98/2             98/2              97/3              .84
  *EPHA1* rs11771145, % 0/1/2          44/44/12         45/42/13          43/44/13          .94
  *EPHA1* rs11767557, % 0/1/2          66/30/4          70/27/3           63/34/3           .29
  *MS4A6A* rs610932, % 0/1/2           31/48/21         37/47/16          38/45/17          .25
  *NME8* rs2718058, % 0/1/2            39/47/14         40/45/15          38/49/13          .88
  *PTK2B* rs28834970, % 0/1/2          42/42/16         42/42/16          39/49/12          .39
  *SLC24A4/RIN3* rs10498633, % 0/1/2   61/34/5          62/34/4           58/37/5           .87
  *SORL1* rs11218343, % 0/1            91/9             92/8              93/7              .55

Abbreviations: FDG PET, F18-fluorodeoxyglucose positron emission tomography; NC, normal control; MCI, mild cognitive impairment; DEM, dementia; SD, standard deviation; MMSE, Mini--Mental State Examination.

NOTE. Bold text indicates a significant *P* value (*P* \<0.05).

###### 

Family-wise error (FWE) and false discovery rate (FDR)-corrected cluster analyses and within-cluster peak effects for the genetic variants identified in the exploratory MRI analyses

  DX group                    Gene variant        Cluster-level   Peak level     Talairach coordinates   Brain region (Brodmann area \[BA\])                                                                         
  --------------------------- ------------------- --------------- -------------- ----------------------- ------------------------------------- ------------- --------------------------- --------------------------- ------------------------------
  DEM                         *ABCA7* rs3752246   **\<.0001**     **\<0.0001**   924757                  **\<.0001**                           9.72          **\<.0001**                 −11 −23 63                  L medial frontal gyrus (BA6)
  *EPHA1* rs11771145          **.04**             0.051           13,081         **.001**                3.86                                  **\<.0001**   −52 −28 61                  L postcentral gyrus (BA2)   
  **.007**                    **0.017**           1889            **\<.0001**    4.01                    **\<.0001**                           52 −30 59     R postcentral gyrus (BA2)                               
  *SLC24A4/RIN3* rs10498633   **.007**            **0.012**       18,621         **\<.0001**             3.78                                  **\<.0001**   −14 1 46                    L cingulate gyrus (BA24)    

Abbreviations: MRI, magnetic resonance imaging; *p*FWE-corr, family-wise error-corrected *P*-value; *q*FDR-corr, false discovery rate--corrected q-value; *k*E, cluster size; *p*~uncorr~, uncorrected *P*-value; *T*, T statistic; DEM, dementia.

NOTE. Bold text indicates a significant *P* value (*P* \<0.05).

###### 

Family-wise error (FWE) and false discovery rate (FDR)-corrected cluster-level analyses and within-cluster peak effects for genetic variants identified in the exploratory FDG PET analyses

  Diagnostic group            Gene variant         Cluster        Peak effect    Talairach coordinates   Brain region (Brodmann area \[BA\])                                                                                          
  --------------------------- -------------------- -------------- -------------- ----------------------- ------------------------------------- ------------- ------------------------------------ ----------------------------------- ----------------------------------
  Pooled sample               *CLU* rs1113600      **\<.0001**    **\<0.0001**   5979                    **\<.0001**                           4.02          **\<.0001**                          −48 −4 −32                          L inferior temporal gyrus (BA20)
  **.027**                    **0.025**            1493           **\<.0001**    4.01                    **\<.0001**                           64 −18 8      R transverse temporal gyrus (BA42)                                       
  *EPHA1* rs11771145          **.049**             0.102          1314           **.0001**               3.8                                   **\<.0001**   −14 −50 60                           L superior parietal lobule (BA7)    
  *MS4A6A* rs610932           **.001**             **0.001**      2723           **\<.0001**             4.28                                  **\<.0001**   40 −14 42                            R precentral gyrus (BA4)            
  *PTK2B* rs28834970          **.002**             **0.003**      2426           **\<.0001**             3.96                                  **\<.0001**   −2 −74 −2                            L lingual gyrus (BA18)              
  NC                          *CELF1* rs10838725   **.004**       **0.004**      1960                    **\<.0001**                           4.19          **\<.0001**                          20 −66 44                           R precuneus (BA7)
  **\<.0001**                 **\<0.0001**         2718           **\<.0001**    3.88                    **\<.0001**                           0 52 −12      L medial frontal gyrus (BA10)                                            
  **.017**                    **0.012**            1514           **\<.0001**    3.5                     **\<.0001**                           32 −38 −4     R subgyral, hippocampus                                                  
  *CR1* rs12034383            **\<.0001**          **\<0.0001**   37,014         **\<.0001**             4.98                                  **\<.0001**   18 −36 30                            R cingulate gyrus (BA31)            
  *DSG2* rs8093731            **.017**             **0.008**      1515           **\<.0001**             4.15                                  **\<.0001**   6 −4 50                              R medial frontal gyrus (BA6)        
  *PTK2B* rs28834970          **\<.0001**          **\<0.0001**   6279           **\<.0001**             4.24                                  **\<.0001**   44 −22 6                             L superior temproral gyrus (BA13)   
  **\<.0001**                 **\<0.0001**         6722           **\<.0001**    3.98                    **\<.0001**                           −42 −36 12    L superior temproral gyrus (BA41)                                        
  *SLC24A4/RIN3* rs10498633   **\<.0001**          **\<0.0001**   20,054         **\<.0001**             4.38                                  **\<.0001**   22 −4 −30                            R parahippocampal gyrus (BA36)      
  **.007**                    **0.004**            1767           **\<.001**     3.71                    **\<.0001**                           −22 −8 −30    L parahippocampal gyrus (BA36)                                           
  DEM                         *NME8* rs2718058     **\<.001**     **\<0.001**    3551                    **\<.001**                            4.52          **\<.0001**                          −14 −88 30                          L cuneus (BA19)

Abbreviations: FDG PET, F18-fluorodeoxyglucose positron emission tomography; *p*FWE-corr, family-wise error-corrected *P*-value; *q*FDR-corr, false discovery rate--corrected q-value; *k*E, cluster size; *p*~uncorr~, uncorrected *P*-value; *T*, T statistic; NC, normal control; DEM, dementia.

NOTE. Bold text indicates a significant *P* value (*P* \<0.05).

[^1]: Indicates co-first authorship.

[^2]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#intref0010}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.
